SEARCH

SEARCH BY CITATION

References

  • Adams CE, Eisenbruch M (2000). Depot fluphenazine for schizophrenia. Cochrane Database Syst Rev CD000307.
  • Anttila SA, Leinonen EV (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7: 249264.
  • Appell RA, Sand P, Dmochowski R et al (2001). Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 76: 358363.
  • Atkinson JC, Shiroky JB, Macynski A, Fox PC (1989). Effects of furosemide on the oral cavity. Gerodontology 8: 2326.
  • Bagheri H, Schmitt L, Berlan M, Montastruc JL (1997). A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Eur J Clin Pharmacol 52: 339342.
  • Bergdahl M, Bergdahl J (2000). Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 79: 16521658.
  • Boozer CN, Daly PA, Homel P et al (2002). Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 26: 593604.
  • Boyd LD, Dwyer JT, Papas A (1997). Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. Nutr Rev 55: 362368.
  • Bray GA (2001). Drug treatment of obesity. Rev Endocr Metab Disord 2: 403418.
  • Bruera E, Belzile M, Neumann CM, Ford I, Harsanyi Z, Darke A (1999). Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial. Support Care Cancer 7: 280283.
  • Busto UE, Sproule BA, Knight K, Herrmann N (2001). Use of prescription and nonprescription hypnotics in a Canadian elderly population. Can J Clin Pharmacol 8: 213221.
  • Carlson GW (2000). The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am 80: 261273.
  • Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge, SS, Witek TJ Jr (2000). The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118: 12941302.
  • Cauda R, Tacconelli E, Tumbarello M et al (1999). Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 21: 2025.
  • Chacko RC, Marsh BJ, Marmion J, Dworkin RJ, Telschow R (1987). Lithium side effects in elderly bipolar outpatients. Hillside J Clin Psychiatry 9: 7988.
  • Chi KH, Myers JN, Chow KC et al (2001). Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60: 110115.
  • Christodoulou GN, Siafakas A, Rinieris PM (1977). Side-effects of lithium. Acta Psychiatr Belg 77: 260266.
  • Clemett D, Jarvis B (2001). Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18: 277304.
  • Comer AM, Goa KL (2000). Extended-release oxybutynin. Drugs Aging 16: 149155.
  • Conant MA, Opp KM, Poretz D, Mills, RG (1997). Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 11: 13001301.
  • Consroe P, Sandyk R, Snider SR (1986). Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30: 277282.
  • Conti L, Pinder RM (1979). A controlled comparative trial of mianserin and diazepam in the treatment of anxiety states in psychiatric out-patients. J Int Med Res 7: 285289.
  • Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr (2000). Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 7: 211217.
  • Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA (1999). A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21: 643658.
  • Davies AN, Broadley K, Beighton D (2001). Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22: 820825.
  • Davis R, Faulds D (1996). Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 52: 696724.
  • Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63: 308315.
  • Di Giovanni J (1990). Drugs and the geriatric patient: a review of problems and special considerations faced by the dentist. Spec Care Dentist 10: 161163.
  • Dickstein K, Manhenke C, Aarsland T, McNay J, Wiltse C, Wright T (2000). The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. Int J Cardiol 75: 167176.
  • Dios PD, Scully C (2002). Adverse effects of antiretroviral therapies: focus on orofacial effects. Expert opinions on drug safety 1: 304317.
  • Dodd CL, Greenspan D, Westenhouse JL, Katz MH (1992). Xerostomia associated with didanosine. Lancet 340: 790 .
  • Dolberg OT, Klag E, Gross Y, Schreiber S (2002). Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. Psychopharmacology (Berl) 161: 404407.
  • Duggan L, Fenton M, Dardennes RM, El Dosoky A, Indran S (2000). Olanzapine for schizophrenia. Cochrane Database Syst Rev CD001359.
  • Elie R, Lamontagne Y (1984). Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 4: 125129.
  • Ellingrod VL, Perry PJ (1994). Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 51: 30333046.
  • Feighner JP (1999). Mechanism of action of antidepressant medications. J Clin Psychiatry 60 (Suppl. 4): 411.
  • Feighner JP, Overo K (1999). Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 60: 824830.
  • Ferraccioli GF, Salaffi F, De Vita S et al (1996). Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 14: 367371.
  • Field EA, Fear S, Higham SM et al (2001). Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice. Gerodontology 18: 2124.
  • Fox PC (1998). Acquired salivary dysfunction. Drugs and radiation. Ann NY Acad Sci 842: 132137.
  • Freye E, Baranowski J, Latasch L (2001). Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers. Arzneimittelforschung 51: 6066.
  • Friedlander AH, Birch NJ (1990). Dental conditions in patients with bipolar disorder on long-term lithium maintenance therapy. Spec Care Dentist 10: 148151.
  • Garely AD, Burrows LJ (2002). Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 3: 827833.
  • Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283: 30823088.
  • Goodman GE, Alberts DS, Earnst DL, Meyskens FL (1983). Phase I trial of retinol in cancer patients. J Clin Oncol 1: 394399.
  • Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A (2001). The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 15: 167172.
  • Greenwood I, Heylen R, Zakrzewska JM (1998). Anti-retroviral drugs–implications for dental prescribing. Br Dent J 184: 478482.
  • Grotenhermen F (1999). [The effects of cannabis and THC]. Forsch.Komplementarmed. 6 (Suppl. 3): 711.
  • Gupta SK, Sathyan G (1999). Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39: 289296.
  • Gwaltney JM Jr, Park J, Paul RA, Edelman DA, O'Connor RR, Turner RB (1996). Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis 22: 656662.
  • Harvey MA, Baker K, Wells GA (2001). Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 185: 5661.
  • Hay-Smith J, Herbison P, Ellis G, Moore K (2002). Anticholinergic drugs versus placebo for overactive bladder syndrome in adults (Cochrane Review). Cochrane Database Syst Rev CD003781.
  • Hazell P, O'Connell D, Heathcote D, Henry D (2002). Tricyclic drugs for depression in children and adolescents (Cochrane Review). Cochrane Database Syst Rev CD002317.
  • Hennes R, Mack A, Schell H, Vogt HJ (1984). 13-cis-retinoic acid in conglobate acne. A follow-up study of 14 trial centers. Arch Dermatol Res 276: 209215.
  • Howe AM (1995). Methamphetamine and childhood and adolescent caries. Aust Dent J 40: 340.
  • Hunter KD, Wilson WS (1995). The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 40: 983989.
  • Jacobsen FM, Comas-Diaz L (1999). Donepezil for psychotropic-induced memory loss. J Clin Psychiatry 60: 698704.
  • Jacquetin B, Wyndaele J (2001). Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 98: 97102.
  • Johnston JA, Fiedler-Kelly J, Glover ED et al (2001). Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 3: 131140.
  • Kaiser HB, Banov CH, Berkowitz RR et al (1998). Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther 5: 245251.
  • Kaviani MJ, Malekzadeh R, Vahedi H et al (2001). Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol 13: 915919.
  • Kawaguchi M, Yamagishi H (1995). Receptive systems for drugs in salivary gland cells. Nippon Yakurigaku Zasshi 105: 295303.
  • Lader MH (1996). Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 57 (Suppl. 2): 3944.
  • Laine P, Meurman JH, Tenovuo, J et al (1992). Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs. Eur J Cancer B Oral Oncol 28B: 125128.
  • Laine K, Tybring G, Hartter S et al (2001). Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 70: 327335.
  • Layton D, Pearce GL, Shakir SA (2001). Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf 24: 703713.
  • Lee E, Lee C (1997). Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80: 606611.
  • Loesche WJ, Bromberg J, Terpenning MS et al (1995). Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. J Am Geriatr Soc 43: 401407.
  • McCarron DA (1984). Step-one antihypertensive therapy: a comparison of a centrally acting agent and a diuretic. J Cardiovasc Pharmacol 6 (Suppl. 5): S853S858.
  • McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI (1998). Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 34: 484490.
  • Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G (1995). Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 75: 452456.
  • Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K (1999). A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84: 646651.
  • Madinier I, Jehl-Pietri C, Monteìl RA (1997). Drug-induced xerostomia. Ann Med Interne (Paris) 148: 398405.
  • Malone-Lee JG, Walsh JB, Maugourd MF (2001). Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 49: 700705.
  • Mangrella M, Motola G, Russo F et al (1998). Hospital intensive monitoring of adverse reactions of ACE inhibitors. Minerva Med 89: 9197.
  • Matsui M, Motomura D, Karasawa H et al (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 97: 95799584.
  • Mattila MJ, Paakkari I (1999). Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 55: 8593.
  • Mavissakalian M, Perel J, Guo S (2002). Specific side effects of long-term imipramine management of panic disorder. J Clin Psychopharmacol 22: 155161.
  • Meaney PJ (1997). Methadone and caries. Aust Dent J 42: 138.
  • Meurman JH, Collin HL, Niskanen L et al (1998). Saliva in non-insulin-dependent diabetic patients and control subjects: the role of the autonomic nervous system. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86: 6976.
  • Milosevic A, Agrawal N, Redfearn P, Mair L (1999). The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). Community Dent Oral Epidemiol 27: 283287.
  • Mullen J, Jibson MD, Sweitzer D (2001). A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23: 18391854.
  • Nagler RM (1998). Effects of radiotherapy and chemotherapeutic cytokines on a human salivary cell line. Anticancer Res 18: 309314.
  • Nagler A, Nagler R, Ackerstein A, Levi S, Marmary Y (1997). Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 20: 575580.
  • Nagler RM, Gez E, Rubinov R et al (2001). The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma. Arch Oral Biol 46: 487493.
  • Narhi TO, Meurman JH, Ainamo A (1999). Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging 15: 103116.
  • Nederfors T (1996). Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. Swed Dent J Suppl 116: 170.
  • Noguchi K, Masuda M, Noguchi S et al (1998). Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence. Hinyokika Kiyo 44: 687693.
  • Oikarinen K, Salo T, Kylmaniemi M, Palatsi R, Karhunen T, Oikarinen A (1995). Systemic oral isotretinoin therapy and flow rate, pH, and matrix metalloproteinase-9 activity of stimulated saliva. Acta Odontol Scand 53: 369371.
  • Pajukoski H, Meurman JH, Halonen P, Sulkava R (2001). Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92: 641649.
  • Peroutka SJ, Newman H, Harris H (1988). Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1: 273277.
  • Persson RE, Izutsu KT, Treulove EL, Persson R (1991). Differences in salivary flow rates in elderly subjects using xerostomatic medications. Oral Surg Oral Med Oral Pathol 72: 4246.
  • Pomara N, Shao B, Choi SJ, Tun H, Suckow RF (2001). Sex-related differences in nortriptyline-induced side-effects among depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 25: 10351048.
  • Porter SR, Scully C (1998). HIV topic update: protease inhibitor therapy and oral health care. Oral Dis 4: 159163.
  • Potgieter GE, Groenewoud G, Jordaan PJ, Hundt HK, Schall R, Kummer M, Sewarte-Ross G (2002). Pharmacokinetics of pipamperone from three different tablet formulations. Arzneimittelforschung 52: 430434.
  • Rafaelsen OJ, Clemmesen L, Lund H, Mikkelsen PL, Bolwig TG (1981). Comparison of peripheral anticholinergic effects of antidepressants: dry mouth. Acta Psychiatr Scand 290 (Suppl.): 364369.
  • Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH (1997). A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 58: 112118.
  • Reid JL (2001). Update on rilmenidine: clinical benefits. Am J Hypertens 14: 322S324S.
  • Richter WO (1999). How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine. MMW Fortschr Med 141: 3236.
  • Roger M, Gerard D, Leger JM (1998). Value of tiapride for agitation in the elderly. Review of published studies. Encephale 24: 462468.
  • Roth MT, Westman EC (2001). Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. Pharmacotherapy 21: 636641.
  • Sathyan G, Chancellor MB, Gupta SK (2001). Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 52: 409417.
  • Schachter M (1999). Moxonidine: a review of safety and tolerability after seven years of clinical experience. J Hypertens 17 (Suppl. 3): S37S39.
  • Schatzberg AF (2000). Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61 (Suppl. 10): 3138.
  • Scott LJ, Perry CM (2000). Tramadol: a review of its use in perioperative pain. Drugs 60: 139176.
  • Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y (1999). Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 55: 583587.
  • Semenchuk MR, Sherman S, Davis B (2001). Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57: 15831588.
  • Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R (1994). Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14: 322329.
  • Skopouli FN, Moutsopoulos HM (1995). Cytokines in Sjogren's syndrome. Ann Med Interne (Paris) 146: 219222.
  • Smith RG, Burtner AP (1994). Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist 14: 96102.
  • Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S (1999). The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 14: 851857.
  • Sreebny LM, Schwartz SS (1997). A reference guide to drugs and dry mouth. 2nd edn. Gerodontology 14: 3347.
  • Srisurapanont M, Disayavanish C, Taimkaew K (2000). Quetiapine for schizophrenia. Cochrane Database Syst Rev CD000967.
  • Streckfus CF (1995). Salivary function and hypertension: a review of the literature and a case report. J Am Dent Assoc 126: 10121017.
  • Taricco M, Adone R, Pagliacci C, Telaro E (2000). Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev CD001131.
  • Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ, Thompson RP (1995). Omeprazole and dry mouth. Scand J Gastroenterol 30: 216218.
  • Thomson WM, Slade GD, Spencer AJ (1995). Dental caries experience and use of prescription medications among people aged 60+ in South Australia. Gerodontology 12: 104110.
  • Thomson WM, Chalmers JM, Spencer AJ, Slade GD (2000). Medication and dry mouth: findings from a cohort study of older people. J Public Health Dent 60: 1220.
  • Thomson WM, Spencer AJ, Slade GD, Chalmers JM (2002). Is medication a risk factor for dental caries among older people? Community Dent Oral Epidemiol 30: 224232.
  • Tincello DG, Adams EJ, Sutherst JR, Richmond DH (2000). Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. BJU Int 85: 416420.
  • Tohen M, Chengappa KN, Suppes T et al (2002). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59: 6269.
  • Tollefson GD, Birkett MA, Kiesler GM, Wood AJ (2001). Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49: 5263.
  • Trindade E, Menon D, Topfer LA, Coloma C (1998). Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159: 12451252.
  • Turner RJ, Sugiya H (2002). Understanding salivary fluid and protein secretion. Oral Dis 8: 311.
  • Valentine C, Deenmamode J, Sherwood R (1992). Xerostomia associated with didanosine. Lancet 340: 15421543.
  • Versi E, Appell R, Mobley D, Patton W, Saltzstein D (2000). Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 95: 718721.
  • Versiani M, Cassano G, Perugi G et al (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63: 3137.
  • Vissink A, van Nieuw Amerongen A, Wesseling H, ’s-Gravenmade EJ (1992). Dry mouth; possible cause – pharmaceuticals. Ned Tijdschr Tandheelkd 99: 103112.
  • Wadworth AN, McTavish D (1993). Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 3: 441459.
  • Wahlbeck K, Cheine M, Essali MA (2000). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev CD000059.
  • Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM, Ascher JA (2000). Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61: 196202.
  • Weintraub M, Sundaresan PR, Schuster B et al (1992). Long-term weight control study. II (weeks 34 to 104) An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 51: 595601.
  • Weir A, Wansbrough-Jones M (1997). Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 11: 18951896.
  • Wellington K, Jarvis B (2001). Cetirizine/pseudoephedrine. Drugs 61: 22312240.
  • Wellington K, Perry CM (2001). Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 15: 643669.
  • Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK (2002). Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 42: 4955.
  • Wishart JM, Hodge JL, Greig DE (1981). Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro-10–9359). Tigason NZ Med J 94: 307308.
  • Wynn RL, Meiller TF (2001). Drugs and dry mouth. Gen Dent 49: 1014.
  • Zacny JP (2001). Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend 63: 2328.
  • Zinner NR, Mattiasson A, Stanton SL (2002). Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 50: 799807.
  • Zwar N, Richmond R (2002). Bupropion sustained release. A therapeutic review of Zyban. Aust Fam Physician 31: 443447.
  • van Zwieten PA (1999). Centrally acting antihypertensive drugs. Present and future. Clin Exp Hypertens 21: 859873.
  • van Zwieten PA (2000). Renewed interest in centrally acting antihypertensive drugs. Cardiovasc J S Afr 11: 225229.